Budesonide oral suspension - Takeda
Alternative Names: Eohilia; Oral viscous budesonide; SHP-621; TAK-721Latest Information Update: 20 Jan 2025
At a glance
- Originator Verus Pharmaceuticals
- Developer Takeda
- Class Alcohols; Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Dioxoles; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Eosinophilic oesophagitis
Most Recent Events
- 08 Sep 2024 Adverse events and pharmacokinetics data from a phase I trial in healthy volunteers presented at the American College of Clinical Pharmacology Annual Meeting (ACCP -2024)
- 28 Aug 2024 Launched for Eosinophilic oesophagitis (In adolescents, In children, In the elderly, In adults) in USA (PO), prior to August 2024
- 15 Feb 2024 Takeda plans to launch budesonide oral suspension for Eosinophilic esophagitis, by end of February 2024